Contract development and manufacturing of pharmaceuticals is at the core of Prange Pharma’s business.
With its own production facilities and minority shareholdings in Adragos Pharma and Aenova, Prange Pharma is firmly established in the CDMO sector.
As the former owner of the Haupt Pharma Group, the company has played a significant role in shaping the European CDMO landscape for decades.
Long-term partnerships in the CDMO sector
Through majority shareholdings in Halden Pharma and Aprilia Animal Health, Prange Pharma maintains close operational proximity to manufacturing and a deep understanding of production processes – in both human and veterinary medicine. Across all CDMO activities, Prange Pharma is guided by a clear commitment to long-term partnerships, high quality standards, and reliable performance. As a trusted partner to customers and stakeholders, the company is dedicated to operational excellence with a long-term perspective.
Technological Expertise and CDMO Services
Manufacturing Technologies and Dosage Forms
- Sterile manufacturing
- Non-sterile manufacturing
- Broad range of dosage forms
- Human and veterinary medicinal products
End-to-End CDMO Services
- Technology and process transfer
- Validation services
- Analytical services and stability studies
- Commercial manufacturing and packaging
- QP release, regulatory support, and lifecycle management
Quality and Regulatory Standards
- cGMP-certified manufacturing facilities
- Compliance with international regulatory requirements (EU GMP, U.S. FDA, and others)
Contract Development and Manufacturing (CDMO)
Learn more about our CDMO manufacturing facilities and their specific technological capabilities
Core Competencies
- Sterile manufacturing (LVP & SVP): Large-volume infusion solutions (50–5,000 ml), blow-fill-seal ampoules and vials, terminal sterilisation, and batch sizes of up to 15,000 litres
- Non-sterile liquids and gels: Manufacturing and filling of batches up to 5,300 litres, including ATEX-compliant products
- Aseptic manufacturing processes: Compounding using isolator technology
Services
- Technology transfer and process validation
- Analytical services, stability programmes, and quality control
- Commercial manufacturing and packaging
- QP release and regulatory support
Aprilia Animal Health S.r.l.
Via Nettunense Km 20.238, snc
04011 Aprilia (LT), Italy
www.aprilia-ah.com
Core competencies:
- Sterile forms: suspensions, solutions, powders (aseptic compounding, terminal sterilization/irradiation)
- Non-sterile forms: solutions, ointments, powders, sprays, animal feed, ectoparasiticides
- Packaging: Glass and PET vials, pipettes and blisters, aerosol spray cans, bottles, cans, pouches, tubes
Services:
- Technology transfer and method transfer
- Process, cleaning, and scale-up validation
- Stability testing according to ICH
- Regulatory support and lifecycle management
Core Competencies:
- Sterile Production: Aseptic filling (fill & finish) of sterile liquids, including ampoules and vials
- Lyophilization: Manufacture of lyophilized and liquid sterile (bio)pharmaceuticals
- Non-sterile Formulations: Production of non-sterile liquid and semisolid pharmaceuticals
Services:
- Technology Transfer & Scale-up
- Analytics & Stability Studies
- Clinical manufacturing (aseptic filling)
Core Competencies:
- Full-service CDMO: Development and production across all common dosage forms (solid, semisolid, liquid; sterile and non-sterile)
- Broad technology and format portfolio: including tablets/hard capsules as well as sterile technologies (e.g., vials/lyophilized products, pre-filled syringes)
- Development & Technology Services: Drug development, analytical development, regulatory support, and technology transfer
Services:
- Product Development
- Manufacturing & Analytics
- Packaging & Logistics (including market release)
*Minority Interests